These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 7726523)

  • 1. Pharmacokinetics and tissue penetration of the new fluoroquinolone grepafloxacin.
    Child J; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1995 Feb; 39(2):513-5. PubMed ID: 7726523
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics and inflammatory fluid penetration of sparfloxacin.
    Johnson JH; Cooper MA; Andrews JM; Wise R
    Antimicrob Agents Chemother; 1992 Nov; 36(11):2444-6. PubMed ID: 1336947
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and penetration into inflammatory fluid of trovafloxacin (CP-99,219).
    Wise R; Mortiboy D; Child J; Andrews JM
    Antimicrob Agents Chemother; 1996 Jan; 40(1):47-9. PubMed ID: 8787877
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetics of grepafloxacin after oral administration of single and repeat doses in healthy young males.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():1-8. PubMed ID: 9433650
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics of grepafloxacin.
    Efthymiopoulos C
    J Antimicrob Chemother; 1997 Dec; 40 Suppl A():35-43. PubMed ID: 9484872
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics and inflammatory fluid penetration of clinafloxacin.
    Wise R; Jones S; Das I; Andrews JM
    Antimicrob Agents Chemother; 1998 Feb; 42(2):428-30. PubMed ID: 9527799
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Grepafloxacin pharmacokinetics in individuals with hepatic dysfunction.
    Efthymiopoulos C; Bramer SL; Maroli A; Flaherty JF; Wolfe E; Bass N; Somberg K
    Clin Pharmacokinet; 1997; 33 Suppl 1():25-31. PubMed ID: 9433653
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics and tissue penetration of orally administered lomefloxacin.
    Stone JW; Andrews JM; Ashby JP; Griggs D; Wise R
    Antimicrob Agents Chemother; 1988 Oct; 32(10):1508-10. PubMed ID: 3190181
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of age and gender on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():9-17. PubMed ID: 9433651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Theophylline and warfarin interaction studies with grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A; Blum B
    Clin Pharmacokinet; 1997; 33 Suppl 1():39-46. PubMed ID: 9433655
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Grepafloxacin.
    Wagstaff AJ; Balfour JA
    Drugs; 1997 May; 53(5):817-24; discussion 825-7. PubMed ID: 9129868
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparative study of pharmacokinetics of two new fluoroquinolones, balofloxacin and grepafloxacin, in elderly subjects.
    Kozawa O; Uematsu T; Matsuno H; Niwa M; Nagashima S; Kanamaru M
    Antimicrob Agents Chemother; 1996 Dec; 40(12):2824-8. PubMed ID: 9124849
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A study to determine the pharmacokinetics and inflammatory fluid penetration of gatifloxacin following a single oral dose.
    Wise R; Andrews JM; Ashby JP; Marshall J
    J Antimicrob Chemother; 1999 Nov; 44(5):701-4. PubMed ID: 10552990
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The in-vitro activity, pharmacokinetics and tissue penetration of temafloxacin.
    Nye K; Shi YG; Andrews JM; Ashby JP; Wise R
    J Antimicrob Chemother; 1989 Sep; 24(3):415-24. PubMed ID: 2808194
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and tissue penetration of orally administered pefloxacin.
    Webberley JM; Andrews JM; Ashby JP; McLeod A; Wise R
    Eur J Clin Microbiol; 1987 Oct; 6(5):521-4. PubMed ID: 3481335
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of food and gastric pH on the bioavailability of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A
    Clin Pharmacokinet; 1997; 33 Suppl 1():18-24. PubMed ID: 9433652
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics and tissue penetration of rufloxacin, a long acting quinolone antimicrobial agent.
    Wise R; Johnson J; O'Sullivan N; Andrews JM; Imbimbo BP
    J Antimicrob Chemother; 1991 Dec; 28(6):905-9. PubMed ID: 1667783
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and tissue penetration of gemifloxacin following a single oral dose.
    Gee T; Andrews JM; Ashby JP; Marshall G; Wise R
    J Antimicrob Chemother; 2001 Apr; 47(4):431-4. PubMed ID: 11266415
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of renal impairment on the pharmacokinetics of grepafloxacin.
    Efthymiopoulos C; Bramer SL; Maroli A; Gambertoglio JG
    Clin Pharmacokinet; 1997; 33 Suppl 1():32-8. PubMed ID: 9433654
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single- and multiple-dose pharmacokinetics of AM-1155, a new 6-fluoro-8-methoxy quinolone, in humans.
    Nakashima M; Uematsu T; Kosuge K; Kusajima H; Ooie T; Masuda Y; Ishida R; Uchida H
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2635-40. PubMed ID: 8592993
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.